On March 20, 2025, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for Fabhalta (iptacopan). This approval, categorized as an Efficacy supplement (NDA 218276 S-4), indicates an update related to the drug's effectiveness.
Background
Iptacopan, marketed under the brand name Fabhalta, is developed by Novartis. The FDA's supplemental approval specifically addresses aspects of the drug's efficacy.
What this means
This supplemental approval for Fabhalta (iptacopan) signifies an update to the drug's approved uses or conditions of use, specifically regarding its efficacy. Clinicians, researchers, and patient advocates should consult the updated label for precise details on any expanded or modified indications or patient populations.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on March 20, 2025. Details are available on the FDA's website at accessdata.fda.gov.